Recent advances in the management of dry age-related macular degeneration: A review

F1000Research

Volumn 6, Issue , 2017, Pages

  Querques, Giuseppe ^a   Bandello, Francesco ^a   Sacconi, Riccardo ^a,b   Querques, Lea ^a   Corbelli, Eleonora ^a   Cicinelli, Maria Vittoria ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Age related macular degeneration; Anti inflammatory agents; Dry AMD; Geographic atrophy; Lipofuscin; Neuroprotective therapy; Nutritional Supplements; Stem cell based therapy

Indexed keywords

AGENTS ACTING ON THE EYE; ANTIINFLAMMATORY AGENT; AVACINCAPTAD PEGOL; BRIMONIDINE; COMPLEMENT INHIBITOR; ECULIZUMAB; EMIXUSTAT; GLATIRAMER; GSK 933776; LIPOFUSCIN; MC 1101; MOXAVERINE; NEUROPROTECTIVE AGENT; NUTRITION SUPPLEMENT; POT 4; PROSTAGLANDIN E1; RAPAMYCIN; RN 6G; SILDENAFIL; UNCLASSIFIED DRUG; VASODILATOR AGENT; VISUAL CYCLE INHIBITOR;

AGE RELATED MACULAR DEGENERATION; AUTOFLUORESCENCE IMAGING; BIOLOGICAL MONITORING; CHRONIC INFLAMMATION; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; EYE BLOOD FLOW; FOLLOW UP; GEOGRAPHIC ATROPHY; HUMAN; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY; OXIDATIVE STRESS; PATHOGENESIS; PHOTORECEPTOR; RETINAL PIGMENT EPITHELIUM; REVIEW; STEM CELL TRANSPLANTATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 85019649385     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.10664.1     Document Type: Review

References (69)

1. Congdon N O'Colmain B Klaver CC: Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-485. 15078664 10.1001/archopht.122.4.477
2. Klein R Klein BE Lee KE: Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol. 2006;142(4):539-549. 17011842 10.1016/j.ajo.2006.06.015
3. Gehrs KM Jackson JR Brown EN: Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol. 2010;128(3):349-358. 20212207 10.1001/archophthalmol.2010.18 4405117
4. Lim LS Mitchell P Seddon JM: Age-related macular degeneration. Lancet. 2012;379(9827):1728-1738. 22559899 10.1016/S0140-6736(12)60282-7
5. Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-1436. 11594942 10.1001/archopht.119.10.1417 1462955
6. Couch SM Bakri SJ: Review of combination therapies for neovascular age-related macular degeneration. Semin Ophthalmol. 2011;26(3):114-120. 21609223 10.3109/08820538.2011.577130
7. Lally DR Gerstenblith AT Regillo CD: Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2012;23(3):182-188. 22450218 10.1097/ICU.0b013e328352411c
8. Jo N Mailhos C Ju M: Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006;168(6):2036-2053. 16723717 10.2353/ajpath.2006.050588 1606616
9. Ferris FL 3rd Wilkinson CP Bird A: Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120(4):844-851. 23332590 10.1016/j.ophtha.2012.10.036
10. Arnold JJ Sarks SH Killingsworth MC: Reticular pseudodrusen. A risk factor in age-related maculopathy. Retina. 1995;15(3):183-191. 7569344 10.1097/00006982-199515030-00001
11. Zweifel SA Imamura Y Spaide TC: Prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration. Ophthalmology. 2010;117(9):1775-1781. 20472293 10.1016/j.ophtha.2010.01.027
12. Querques G Massamba N Srour M: Impact of reticular pseudodrusen on macular function. Retina. 2014;34(2):321-329. 23842105 10.1097/IAE.0b013e3182993df1
13. Holz FG Bellman C Staudt S: Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2001;42(5):1051-1056. 11274085
14. Brader HS Ying GS Martin ER: New grading criteria allow for earlier detection of geographic atrophy in clinical trials. Invest Ophthalmol Vis Sci. 2011;52(12):9218-9225. 22039251 10.1167/iovs.11-7493 3302429
15. Schuman SG Koreishi AF Farsiu S: Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in vivo with spectral-domain optical coherence tomography. Ophthalmology. 2009;116(3):488-496.e2. 19167082 10.1016/j.ophtha.2008.10.006 2695995
16. Leuschen JN Schuman SG Winter KP: Spectral-domain optical coherence tomography characteristics of intermediate age-related macular degeneration. Ophthalmology. 2013;120(1):140-150. 22968145 10.1016/j.ophtha.2012.07.004 3536919
17. Christenbury JG Folgar FA O'Connell RV: Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology. 2013;120(5):1038-1045. 23352193 10.1016/j.ophtha.2012.10.018 3640702
18. Yehoshua Z Rosenfeld PJ Gregori G: Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. Ophthalmology. 2011;118(4):679-686. 21035861 10.1016/j.ophtha.2010.08.018 3070862
19. Corvi F Souied EH Capuano V: Choroidal structure in eyes with drusen and reticular pseudodrusen determined by binarisation of optical coherence tomographic images. Br J Ophthalmol. 2016; pii: bjophthalmol-2016-308548. 27190128 10.1136/bjophthalmol-2016-308548
20. Moult EM Waheed NK Novais EA: Swept-source optical coherence tomography angiography reveals choriocapillaris alterations in eyes with nascent geographic atrophy and drusen-associated geographic atrophy. Retina. 2016;36 Suppl 1:S2-S11. 28005659 10.1097/IAE.0000000000001287 5193240
21. Toto L Borrelli E Mastropasqua R: Association between outer retinal alterations and microvascular changes in intermediate stage age-related macular degeneration: an optical coherence tomography angiography study. Br J Ophthalmol. 2016; pii: bjophthalmol-2016-309160. 27625163 10.1136/bjophthalmol-2016-309160
22. Zarbin MA Rosenfeld PJ: Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina. 2010;30(9):1350-1367. 20924259 10.1097/IAE.0b013e3181f57e30
23. Age-Related Eye Disease Study Research Group: Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmolgy. 2000;107(12):2224-2232. 11097601 10.1016/S0161-6420(00)00409-7 1470467
24. Clemons TE Milton RC Klein R: Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology. 2005;112(4):533-539. 15808240 10.1016/j.ophtha.2004.10.047 1513667
25. Omenn GS Goodman GE Thornquist MD: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Nat Cancer Inst. 1996;88(21):1550-1559. 8901853 10.1093/jnci/88.21.1550
26. Age-Related Eye Disease Study 2 Research Group: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005-2015. 23644932 10.1001/jama.2013.4997
27. Ho E Beaver LM Williams DE: Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr. 2011;2(6):497-510. 22332092 10.3945/an.111.001032 3226387
28. Anderson DH Mullins RF Hageman GS: A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134(3):411-431. 12208254 10.1016/S0002-9394(02)01624-0
29. Alimera Sciences: Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy. In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
30. Haines JL Hauser MA Schmidt S: Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308(5720):419-421. 15761120 10.1126/science.1110359
31. Yates JR Sepp T Matharu BK: Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357(6):553-561. 17634448 10.1056/NEJMoa072618
32. Potentia Pharmaceuticals, Inc: Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP). In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
33. Ophthotech Corporation: A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration. In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
34. Yehoshua Z de Amorim Garcia Filho CA Nunes RP: Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014;121(3):693-701. 24289920 10.1016/j.ophtha.2013.09.044 4015213
35. Garcia Filho CA Yehoshua Z Gregori G: Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2014;45(1):18-31. 24354307 10.3928/23258160-20131217-01
36. Genentech, Inc: A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy. In: ClinicalTrials.gov[cited 2017 Jan 24]. Reference Source
37. Roche HL: A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA). In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
38. Roche HL: A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI). In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
39. Wong WT Dresner S Forooghian F: Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci. 2013;54(4):2941-2950. 23548622 10.1167/iovs.13-11650 3638660
40. Kaplan Medical Center: Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration. In: ClinicalTrials.gov[cited 2017 Jan 24]. Reference Source
41. Kaplan Medical Center: Copaxone in Age Related Macular Degeneration. In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
42. Pfizer: Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration. In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
43. GlaxoSmithKline: Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration. In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
44. Tao W Wen R Goddard MB: Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2002;43(10):3292-3298. 12356837
45. Kauper K McGovern C Sherman S: Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2012;53(12):7484-7491. 23049090 10.1167/iovs.12-9970
46. Neurotech Pharmaceuticals: A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration. In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
47. Zhang K Hopkins JJ Heier JS: Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108(15):6241-6245. 21444807 10.1073/pnas.1018987108 3076847
48. WoldeMussie E Ruiz G Wijono M: Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42(12):2849-2855. 11687528
49. Wheeler L WoldeMussie E Lai R: Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003;48 Suppl 1:S47-S51. 12852434 10.1016/S0039-6257(03)00004-3
50. Allergan: Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD). In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
51. Allergan: A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON). In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
52. Brunk UT Terman A: Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med. 2002;33(5):611-619. 12208347 10.1016/S0891-5849(02)00959-0
53. Sirion Therapeutics, Inc: Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration. In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
54. Acucela Inc: Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy. In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
55. Acucela Inc: Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride (SEATTLE). In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
56. Grunwald JE Metelitsina TI Dupont JC: Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci. 2005;46(3):1033-1008. 15728562 10.1167/iovs.04-1050
57. Booij JC Baas DC Beisekeeva J: The dynamic nature of Bruch's membrane. Prog Retin Eye Res. 2010;29(1):1-18. 19747980 10.1016/j.preteyeres.2009.08.003
58. UCB Pharma: Alprostadil in Maculopathy Study (AIMS). In: ClinicalTrials.gov[cited 2017 Jan 24]. Reference Source
59. Augustin AJ Diehm C Grieger F: Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial. Expert Opin Investig Drugs. 2013;22(7):803-812. 23627650 10.1517/13543784.2013.794782
60. MacuCLEAR, Inc: Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration. In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
61. MacuCLEAR, Inc: Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration (McCP2/3). In: ClinicalTrials.gov[cited 2017 Jan 6]. Reference Source
62. Schmidl D Pemp B Lasta M: Effects of orally administered moxaverine on ocular blood flow in healthy subjects. Graefes Arch Clin Exp Ophthalmol. 2013;251(2):515-520. 23203292 10.1007/s00417-012-2207-1
63. Resch H Weigert G Karl K: Effect of systemic moxaverine on ocular blood flow in humans. Acta Ophthalmol. 2009;87(7):731-735. 18778333 10.1111/j.1755-3768.2008.01338.x
64. Pemp B Garhofer G Lasta M: The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects. Acta Ophthalmol. 2012;90(2):139-145. 20456253 10.1111/j.1755-3768.2010.01878.x
65. Metelitsina TI Grunwald JE DuPont JC: Effect of Viagra on the foveolar choroidal circulation of AMD patients. Exp Eye Res. 2005;81(2):159-164. 16080909 10.1016/j.exer.2005.01.017
66. Bhutto I Lutty G: Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol Aspects Med. 2012;33(4):295-317. 22542780 10.1016/j.mam.2012.04.005 3392421
67. Carr AJ Vugler AA Hikita ST: Protective effects of human iPS-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat. PLoS One. 2009;4(12):e8152. 19997644 10.1371/journal.pone.0008152 2780911
68. Cho MS Kim SJ Ku SY: Generation of retinal pigment epithelial cells from human embryonic stem cell-derived spherical neural masses. Stem Cell Res. 2012;9(2):101-109. 22683799 10.1016/j.scr.2012.05.002
69. Buchholz DE Hikita ST Rowland TJ: Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. Stem Cells. 2009;27(10):2427-2434. 19658190 10.1002/stem.189